Skip to main navigation Skip to search Skip to main content

Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients

  • Farrukh T Awan
  • , John M. Pagel
  • , Leslie A Andritsos
  • , Ajay K. Gopal
  • , Richard R. Furman
  • , Stephen Spurgeon
  • , Delva Deauna-Limayo
  • , Scott Stromatt
  • , John C. Byrd
  • Georgia Regents University
  • Fred Hutchinson Cancer Research Center
  • Ohio State University
  • Cornell University
  • Oregon Health & Science University
  • Nevada Cancer Institute
  • Emergent Product Development, Seattle, WA, USA,

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalBlood
Volume118
Issue number21
DOIs
StatePublished - Nov 18 2011
Externally publishedYes

Disciplines

  • Medicine and Health Sciences
  • Gastroenterology
  • Surgery
  • Internal Medicine

Cite this